Showing results (51-60 of 78) with videos related to

Sort By:
Pageof 8
Journal of Medical Virology|May 22, 2020
Epidemiological and clinical characteristics of discharged patients infected with SARS-CoV-2 on the Qinghai PlateauAiqi Xi, Ma Zhuo, Jingtao Dai, et al.
The European Respiratory Journal|June 15, 2023
Translational predictions of phase 2a first-in-patient efficacy studies for antituberculosis drugsJacqueline P Ernest, Janice Jia Ni Goh, Natasha Strydom, et al.
Antimicrobial Agents and Chemotherapy|April 22, 2025
Efficacy of novel regimens targeting oxidative phosphorylation in Mycobacterium tuberculosisDongshuo Li, Liang Li, Ye Zhang, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 23, 2012
Old drugs, new purpose: retooling existing drugs for optimized treatment of resistant tuberculosisKelly E Dooley, Carole D Mitnick, Mary Ann DeGroote, et al.
Tuberculosis (Edinburgh, Scotland)|September 4, 2012
Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosisScott G Franzblau, Mary Ann DeGroote, Sang Hyun Cho, et al.
Bulletin of the World Health Organization|January 7, 2014
Principles for designing future regimens for multidrug-resistant tuberculosisGrania Brigden, Bern-Thomas Nyang'wa, Philipp du Cros, et al.
Frontiers in Pharmacology|July 16, 2021
The Population Pharmacokinetics of Meropenem in Adult Patients With Rifampicin-Sensitive Pulmonary TuberculosisAhmed A Abulfathi, Veronique de Jager, Elana van Brakel, et al.
Plos Medicine|January 4, 2017
Priority-Setting for Novel Drug Regimens to Treat Tuberculosis: An Epidemiologic ModelEmily A Kendall, Sourya Shrestha, Ted Cohen, et al.
Journal of Genetics and Genomics = Yi Chuan Xue Bao|January 25, 2017
Drug resistance mechanisms and novel drug targets for tuberculosis therapyMd Mahmudul Islam, H M Adnan Hameed, Julius Mugweru, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 2, 2025
A Phase 2a Study of the Early Bactericidal Activity of Rifampicin in Combination With Meropenem Plus Amoxicillin/Clavulanate Among Adults With Rifampicin-Resistant Pulmonary TuberculosisVeronique de Jager, Laurynas Mockeliunas, Huifang You, et al.
Pageof 8